(Q35958973)

English

Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

sarcomatoid renal cell carcinoma

0 references

1 reference

based on heuristic

inferred from title

author name string

Michael Staehler

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

N Haseke

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

A Roosen

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

T Stadler

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

M Bader

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

M Siebels

6

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

A Karl

7

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

C G Stief

8

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

language of work or name

0 references

publication date

1 January 2010

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

European Journal of Medical Research

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

15

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

287-291

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

https://scigraph.springernature.com/pub.10.1186/2047-783x-15-7-287

0 references

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

2 October 2017

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

2 October 2017

Renal cell carcinoma guideline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

2 October 2017

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

2 October 2017

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

2 October 2017

Chemotherapy for non-clear-cell renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

2 October 2017

Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

2 October 2017

A phase II study of irinotecan in patients with advanced renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

2 October 2017

Immunotherapy for renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

2 October 2017

Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

2 October 2017

Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

2 October 2017

Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

2 October 2017

Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

2 October 2017

Sustained response of sarcomatoid renal-cell carcinoma to MAID chemotherapy: case report and review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

2 October 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

2 October 2017

Cytotoxic chemotherapy for advanced renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

2 October 2017

Chemotherapy for advanced renal-cell carcinoma: 1983-1993.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

2 October 2017

Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

11 July 2018

Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

24 September 2018

Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

24 September 2018

Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3351952

24 September 2018

Chemotherapy for renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696639

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696639

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696639

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of combination chemotherapy with dacarbazine, cyclophosphamide, cisplatin, doxorubicin, and vindesine (DECAV) in advanced renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696639

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of sarcomatoid renal cell carcinoma: is there a role for chemotherapy?

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696639

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696639

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696639

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696639

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Sarcomatoid renal cell carcinoma. A rare and aggressive variation of primary renal cell carcinoma]

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696639

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NCCN clinical practice guidelines in oncology: kidney cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20696639

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/2047-783X-15-7-287

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35958973&oldid=1996577669"